Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint

NEXT STORY
BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers
PREV STORY
Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study

author_avatar
NASDAQ Market News

CB2 Insights Selected by Drug Science as Research Technology Platform for the UK’s Largest Medical Cannabis Pilot

author_avatar
NASDAQ Market News

Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer

VANCOUVER, British Columbia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a ...

author_avatar
NASDAQ Market News